Submission of intimation of allotment of equity shares in conversion of warrants.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Astal Laboratories Ltd has allotted 9,39,930 equity shares (face value Rs. 10) at Rs. 40 each (including a Rs. 30 premium) upon conversion of equal number of warrants held by non-promoter allottees. The company received approximately Rs. 2.82 crore as the remaining 75% payment on these warrants. This is part of a larger tranche of 37,29,930 warrants originally allotted on a preferential basis on 27th November 2024, of which about 25% have now been converted. The paid-up equity capital of the company has risen from Rs. 9.83 crore to Rs. 10.77 crore. All 11 allottees are non-promoter strategic investors receiving shares through the warrant conversion route.
Shareholders should note a modest dilution of about 9.5% in paid-up equity capital from this conversion tranche. The remaining unconverted warrants (about 27.9 lakh) could cause further dilution if exercised in the future, which may put mild pressure on the stock price in the short term.